Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints. (BioWorld International)

Medarex Inc. could receive up to $530 million through a deal to partner a Phase III metastatic melanoma product with Bristol-Myers Squibb Co. (BioWorld Today)